SIEGFRIED GROUP - Key Persons
Job Titles:
- Chairman of the Board of Directors
- Chairman of the Executive Committee
Andreas Casutt (1963) joined the Board of Siegfried Holding AG in 2010 and was elected Chairman in 2014. He has been a partner of the law firm Niederer Kraft Frey AG in Zurich since 2002, and held office as managing partner from 2006 to 2014. Andreas Casutt specializes in Corporate law, Contract law, Mergers & Acquisitions, and Stock Exchange law. In addition, he is a board member of Mikron Holding AG, maxon international AG, Liechtenstein-based Bendura Bank AG and various privately held companies.
Andreas Casutt studied law and received his Ph.D. in Zurich and completed an LL.M. program at the University of Michigan, Ann Arbor. Andreas Casutt is a Swiss citizen.
Job Titles:
- Chairman of the Board of Directors
Andreas Casutt (1963) joined the Board of Siegfried Holding AG in 2010 and was elected Chairman in 2014. He has been a partner of the law firm Niederer Kraft Frey AG in Zurich since 2002, and held office as managing partner from 2006 to 2014. Andreas Casutt specializes in Corporate law, Contract law, Mergers & Acquisitions, and Stock Exchange law. In addition, he is a board member of Mikron Holding AG, maxon international AG, Liechtenstein-based Bendura Bank AG and various privately held companies.
Andreas Casutt studied law and received his Ph.D. in Zurich and completed an LL.M. program at the University of Michigan, Ann Arbor. Andreas Casutt is a Swiss citizen.
Job Titles:
- Member of the Executive Committee
- Chief Business Officer Drug Substances
Christian Dowdeswell (1966) joined Siegfried in June 2023 as Chief Business Officer Drug Substances. Prior to Siegfried, he has been working at Lonza since 2014, first as Head of Commercial Development for Chemical & Microbial Manufacturing, then as Head of the Dosage Forms & Delivery Systems Business Unit and, since 2020, as Vice President and Global Head of Commercial Development of Lonza's small molecules custom manufacturing business. He had started his career at Maybridge Chemicals, followed by positions with increasing responsibility at Synprotec Ltd, Contract Chemicals, and Dishman Pharmaceuticals & Chemicals where he was VP of Sales Marketing.
Christian Dowdeswell holds a PhD degree in organic chemistry from the University of Teesside (GB).
Christian Dowdeswell is a British citizen.
Job Titles:
- Member of the Board of Directors
Alexandra Brand (1971) joined the Board of Siegfried Holding AG in 2022. She has been holding various senior management positions with Syngenta since 2015. In 2021, she was appointed Regional Director for EAME Crop Protection. In prior functions, she served as Syngenta's Chief Sustainability Officer and as Regional Director, Europe, Africa & Middle East. Prior to joining Syngenta, Alexandra Brand held various positions with increasing importance and responsibility with BASF for more than 15 years. In 2019, Alexandra Brand was elected to the board of directors of Azelis, a PE-owned leading global distributor of specialty chemicals and food ingredients. Alexandra Brand studied Chemistry at the University of Darmstadt, where she also received her Ph.D. in inorganic chemistry in 1998.
Alexandra Brand is a German citizen.
Job Titles:
- Member of the Board of Directors
Beat Walti (1968) joined the Board of Siegfried Holding AG in 2022. He has been a partner of Wenger Vieli, a Zurich-based law firm since 2007, specializing in matters of commercial and corporate law and governance issues. From 1999 to 2013, Beat Walti was a member of the Cantonal Council of Zürich. In 2014, Beat Walti became member to the Swiss National Council, where he belongs to the Economic Affairs and Taxation Committee and also presided over the parliamentary group of "FDP/the liberals" from 2017 - 2022. Beat Walti chairs the Foundation Board of the Ernst Göhner Foundation. He is a member of the board of DSV A/S in Denmark and holds various positions as chairman or member of the board of privately held companies and foundations. In addition, Beat Walti is chairman of the board of OSPITA (Association of Swiss Enterprises in the Healtcare Sector) and member of the board of the Commercial Chamber of the Canton of Zürich and the advisory board of ExpertSuisse, the Swiss expert association for audit, tax and fiduciary.
Beat Walti studied law at the Universities of Neuch tel and Zurich and received his Ph.D. in 1998.
Beat Walti is a Swiss a citizen.
Job Titles:
- Member of the Board of Directors
Elodie Cingari (1974) was elected to the Board of Siegfried Holding AG in 2023. She has been Chief Financial Officer of the Landis+Gyr Group since 2020. Previously, she held the positon of Chief Financial Officer of the Hoerbiger Group. Prior to that, Elodie Cingari spent 11 years with Alstom and later - following the Alstom acquisition - General Electric, where she held several CFO positions of global businesses in the Energy and Grid sectors. She spent the first 10 years of her career with Hewlett-Packard where she held different finance leadership roles.
Elodie Cingari holds a Master of Business Administration from Bocconi University in Milan, Italy. She is a French citizen.
Job Titles:
- Member of the Executive Committee
- Chief Operating Officer Drug Substances
Henrik Krüpper (1971) joined Siegfried in September 2023 as Chief Operating Officer Drug Substances. He started his career at Th. Goldschmidt AG as site excellence and production manager followed by positions with increasing operational and managerial responsibilities at Evonik Industries AG (formerly Degussa AG), City Solar AG, Q-Cells SE and Soltecture GmbH. In 2012, he joined HCS Group, an international specialty chemicals company based in Germany, as Managing Director and Chief Commercial Officer and was appointed Chief Executive Officer in 2019.
Henrik Krüpper holds a diploma (Dipl.-Ing.) in mechanical engineering with a specialization in process engineering from the Technical University (RWTH) Aachen (Germany).
Henrik Krüpper is a German citizen.
Job Titles:
- Chief Human Resources Officer
- Member of the Executive Committee
Irene Wosgien (1973) has been heading Human Resources since July 2023. Before, since January 2021, she was Chief Operating Officer Drug Substances. In 2019, she joined the Siegfried Group as Multi-Site Head for several Drug Substance sites. She has many years of experience in custom manufacturing in the pharmaceutical and food industry.
Before joining Siegfried, Irene Wosgien held various senior management positions at DSM Group, most recently as Vice President Operations Human Nutrition & Health. She holds a Master's degree in chemical engineering from Eindhoven University.
Irene Wosgien is a Dutch citizen.
Job Titles:
- Member of the Board of Directors
Isabelle Welton (1963) was elected to the Board of Siegfried Holding AG in 2020. She is a proven leader with many years of experience in C-level functions of global corporations. The owner of a consulting firm specialising in corporate culture and change processes is Chairman of the Board of Directors of the NZZ Media Group and a member of the Board of Directors of the Avobis Group. She is also a member of the boards of trustees of Swisscontact, SOS Kinderdorf Schweiz and Lucerne Festival. Before becoming self-employed, Isabelle Welton was responsible for Human Resources & Corporate Culture at Zurich Insurance Group as a member of the Group Executive Board until 2017. Prior to that, she worked for IBM, where she held various positions in marketing and communications and finally took over as Country General Manager of IBM Switzerland. Isabelle Welton holds a degree in law from the University of Zurich and has furthered her education at various universities in Australia and the USA.
Isabelle Welton is a Swiss citizen.
Job Titles:
- Chief Scientific Officer
- Member of the Executive Committee
Jürgen Roos (1968) joined the Siegfried Group in April 2019 as Chief Scientific Officer. Before joining Siegfried, Jürgen Roos was working for Evonik Industries AG as Vice President for Innovation Management of the Animal Nutrition business line. Jürgen Roos startet his professional career at Evonik (formerly Degussa-Hüls and Degussa AG) in 1999 as laboratory team leader in chemical research in the field of fine chemicals. After various functions within the R&D organization of Evonik, including several years in Canada and the United Kingdom, Jürgen Roos was appointed head of process development in the field of exclusive synthesis in 2008, and subsequently took over the global responsibility for research and development of Evonik's Health Care division. Jürgen Roos was elected to the Board of Directors of the European Fine Chemicals Group (EFCG), the industry association of European fine chemical manufacturers, where he chairs the Innovation Commitee.
Jürgen Roos studied chemistry at the University of Stuttgart and subsequently obtained a Ph.D. in organic chemistry.
Jürgen Roos is a German citizen.
Job Titles:
- Member of the Executive Committee
- Chief Operating Officer Drug Products / Chief Operating Officer Drug Substances ( Ad Interim )
- Marcel Imwinkelried Chief Operating Officer Drug Products
Marcel Imwinkelried (1967) joined the Siegfried Group in January 2021 as Multi-Site Head for the Drug Products sites in Barberà del Vallès and El Masnou (Spain) as well as Irvine (California) and was appointed Chief Operating Officer Dug Products with effect as per October 2021. Previously, he held various management positions with increasing responsibility and, from 2018, was appointed Global Head Technical Operations Solids.
Marcel Imwinkelried graduated in mechanical engineering from the Lucerne University of Applied Sciences and holds a degree in business administration from the University of St. Gallen.
Marcel Imwinkelried is a Swiss citizen.
Job Titles:
- Member of the Executive Committee
- Chief Business Officer Drug Products
Marianne Späne (1962) joined the Siegfried Group in 2004 and was appointed Chief Business Officer in March 2010. She headed the Siegfried Generics Division from 2008 to 2010. From 2004 to 2008, Marianne Späne managed the Business Development Department and the Supply Chain for Generics. Prior to joining Siegfried, she worked in logistics, business development and as site manager for Boucheron, a cosmetics company. Later, Marianne Späne moved to the pharmaceutical industry and joined the pharma division of Schweizerhalle as Head of the Sales and Marketing department. Subsequently, she joined Aceto, a US-based company, where she developed European expansion strategies.
Marianne Späne holds degrees in finance, business administration and marketing from the Business Management School (KFS) in Basel and the Marketing & Business School in Zurich (MBSZ).
Marianne Späne is a German citizen.
Job Titles:
- Member of the Board of Directors
Martin Schmid (1969) has been a member of the Board of Directors of Siegfried Holding AG since 2016. He was elected State Councillor of the Canton of Graubünden in 2011. From 2003 to 2011 he was a member of the government of the Canton of Graubünden, where he headed the Department of Justice, Security and Health and subsequently the Department of Finance. Martin Schmid is an attorney-at-law. He is a member of the Board of Directors of Swiss Life Holding AG, Repower AG and holds various other directorships in the energy and construction sectors. He also chairs the Swiss Gas Industry Association (VSG ASIG), the Swiss Development Association, the Graubünden Cantonal Hospital Foundation and the Institute of Finance and Financial Law at the University of St. Gallen (IFF-HSG). He is also a member of the board of economiesuisse. He studied law at the University of St. Gallen, where he received his doctorate in 2005.
Martin Schmid is a Swiss citizen.
Job Titles:
- Head Corporate Communications
Job Titles:
- Chief Financial Officer
- Member of the Executive Committee
Reto Suter (1971) joined Siegfried on May 1, 2017, as Chief Financial Officer, additionally responsible for Cyber Security and Risk Management. He is a member of the Board of Directors and Chairman of the Audit Committee of Inficon Holding AG. Over the last 16 years, he held a range of responsible positions in industry as well as in finance and private equity. In his last function as COO, CIO and Board Member of Lonrho, a long-established company headquartered in London (UK) and Johannesburg (SA), Reto Suter was responsible for overseeing the public takeover and subsequent delisting and restructuring. Reto Suter studied economics at the University of Zurich and the University of Washington in Seattle and took his doctorate in banking and finance at the University of Zurich.
Reto Suter is a Swiss Citizen.
Job Titles:
- Chief Executive Officer
- Member of the Executive Committee
Wolfgang Wienand (1972) joined the Siegfried Group in 2010 and was appointed CEO as per January 1, 2019. When joining Siegfried, Wolfgang Wienand first served as Chief Scientific Officer, responsible for Siegfried's global Research & Development activities, before taking over the function as Chief Strategy Officer with responsibility for Strategy, Mergers & Acquisitions, Legal and Intellectual Property Management and Regulatory Affairs in December 2011. From May 2017 until December 2018, he held in parallel both functions, Chief Scientific Officer and Chief Strategy Officer. Before joining Siegfried, Wolfgang Wienand held senior management positions at Evonik Industries AG, formerly Degussa AG, with a focus on fine chemical and custom development & manufacturing for the pharmaceutical industry.
Wolfgang Wienand studied chemistry at the University of Bonn and subsequently obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master's Degree in International Finance of École des hautes études commerciales HEC Paris.
Wolfgang Wienand is a German citizen.
Job Titles:
- Member of the Board of Directors
Wolfram Carius (1961) joined the Board of Siegfried Holding AG in 2014. In October 2020 he was appointed Executive Vice President Pharmaceuticals heading the newly created Cell and Genetherapy unit at Bayer. Since September 2016, he served as Executive Vice President Pharmaceuticals Product Supply at Bayer and member of the Executive Committee at Bayer Pharma. Previously, Wolfram Carius worked for Sanofi, a French healthcare company, as Senior Vice President Biopharma Biologics and member of the Global Leadership Team. From 1987 to 2013, Wolfram Carius held various positions with the pharma company Boehringer Ingelheim. In 2009, he was appointed to the company's Board of Managing Directors, initially with responsibility for Human Resources and Technical Operations, and from 2012 for Biopharma and Operations. Before that, he was responsible for the development and expansion of the biopharma unit. He managed the company's production site in Japan and worked later in Brazil as technical director before being appointed member of Boehringer Ingelheim's Board of Managing Directors in Germany. Wolfram Carius serves at the board of the privately held Uhlmann Group in Germany as well as on the boards of Südpack Medica AG and Ferring Ventures in Switzerland.
Wolfram Carius holds a Ph.D. in Pharmaceutical Biology and Analytical Phytochemistry from the University of Saarland, Germany. In 2009, the Biberach University of Applied Sciences awarded him the title of honorary professor in recognition of his long and exceptional service.
Wolfram Carius is a German citizen.